Treprostinil Sodium CAS 289480-64-4: A Comprehensive Guide to Pulmonary Arterial Hypertension Treatment
Discover the therapeutic benefits and applications of Treprostinil Sodium in managing PAH symptoms and improving patient quality of life.
Get a Quote & SampleProduct Core Value
Treprostinil Sodium
Treprostinil Sodium (CAS 289480-64-4) is a synthetic prostacyclin analog that plays a crucial role in treating Pulmonary Arterial Hypertension (PAH). It functions as a vasodilator, helping to open up blood vessels in the lungs, thereby reducing the pressure and improving blood flow. This leads to a significant reduction in PAH symptoms, particularly those associated with exercise, and can diminish the rate of clinical deterioration in affected patients.
- Explore the efficacy of Treprostinil Sodium in managing PAH symptoms, offering relief from shortness of breath and fatigue, enabling patients to lead more active lives.
- Understand the various administration routes of Treprostinil Sodium, including subcutaneous (SC) and intravenous (IV) infusions, to suit individual patient needs and clinical recommendations.
- Learn about the potential side effects of Treprostinil Sodium, such as infusion site reactions and hypotension, and how they are managed with proper medical guidance.
- Discover cost-saving opportunities with generic Treprostinil Sodium, which offers therapeutic equivalence to branded options, potentially reducing the financial burden on patients.
Key Advantages and Applications
Improved Exercise Capacity
Treprostinil Sodium treatment can significantly improve exercise ability in individuals with PAH, allowing them to engage more actively in daily life by managing pulmonary arterial hypertension drug treprostinil benefits.
Reduced Clinical Deterioration
For patients transitioning from other prostacyclin therapies, Treprostinil Sodium is indicated to slow the rate of clinical deterioration, a critical aspect of treprostinil sodium PAH therapy.
Enhanced Patient Support Systems
Access to comprehensive treprostinil sodium patient support programs, including cost assistance and educational resources, is vital for successful treatment adherence and management.
Key Applications
Pulmonary Arterial Hypertension Treatment
The primary application of Treprostinil Sodium is in the treatment of PAH, a serious condition characterized by high blood pressure in the lung arteries, utilizing its potent vasodilator effects.
Symptom Management
It effectively diminishes symptoms associated with exercise in PAH patients, improving their overall functional capacity and quality of life, a key benefit of treprostinil sodium for exercise intolerance.
Therapeutic Transition Support
Serves as a critical treatment option for patients needing to transition from other prostacyclin treatments, ensuring continuity of care and minimizing the risk of symptom worsening, as highlighted in various treprostinil sodium clinical trials.
Cost-Effective Treatment Option
With the availability of generic versions, Treprostinil Sodium offers a more affordable alternative, addressing concerns related to treprostinil sodium cost savings while maintaining therapeutic efficacy.